Soliqua 100/33
Insulin glargine and lixisenatide · Sanofi-Aventis U.S. LLC
PRESCRIPTION ONLY (USA)Soliqua 100/33 ingredients
| Active ingredient | Strength |
|---|---|
| Insulin Glargine | 100 U/mL |
| Lixisenatide | 33 ug/mL |
What Soliqua 100/33 is used for
Soliqua 100/33 is a specialist medicine (glp-1 receptor agonist, insulin analog). Its approved uses are listed on the official FDA label below.
Key facts
- Brand
- Soliqua 100/33
- Generic name
- Insulin glargine and lixisenatide
- Made by
- Sanofi-Aventis U.S. LLC
- Forms
- Injection, Solution
- Given
- Subcutaneous
- Drug class
- GLP-1 Receptor Agonist, Insulin Analog
- FDA approval
- Biologic licence (BLA) BLA208673
- On the US market since
- 2016
Official information
- Soliqua 100/33 prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Insulin glargine and lixisenatide)
In India
- Insulin glargine: 16 brands in India
- Lixisenatide: 2 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Soliqua 100/33?
Soliqua 100/33 (Insulin glargine and lixisenatide) is a specialist medicine made by Sanofi-Aventis U.S. LLC, approved by the US FDA.
What are the ingredients of Soliqua 100/33?
Soliqua 100/33 contains Insulin Glargine (100 U/mL); Lixisenatide (33 ug/mL).
From the FDA National Drug Code directory (open.fda.gov, public domain). Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA